1
|
Yigit BI, Fernandez-Orth J, Weiss JM, Molnar C, Andrieux G, Gonzalez-Mendez I, Börries M, Niemeyer CM, Teichert-von Lüttichau I, Erlacher M. Identification of functional defects promoting leukemogenesis in
GATA2-deficient individuals. KLINISCHE PADIATRIE 2022. [DOI: 10.1055/s-0042-1748716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- BI Yigit
- University Medical Center Freiburg, Center for Pediatrics, Department
of Pediatric Hematology and Oncology, Freiburg, Germany
- Kinderklinik Muenchen Schwabing, Department of Pediatrics and
Children's Cancer Research Center, TUM School of Medicine, Technical
University of Munich, Munich, Germany
| | - J Fernandez-Orth
- University Medical Center Freiburg, Center for Pediatrics, Department
of Pediatric Hematology and Oncology, Freiburg, Germany
| | - JM Weiss
- University Medical Center Freiburg, Center for Pediatrics, Department
of Pediatric Hematology and Oncology, Freiburg, Germany
| | - C Molnar
- University Medical Center Freiburg, Center for Pediatrics, Department
of Pediatric Hematology and Oncology, Freiburg, Germany
| | - G Andrieux
- University Medical Center Freiburg, Institute of Medical Bioinformatics
und Systems Medicine IBSM, Freiburg, Germany
| | - I Gonzalez-Mendez
- University of Tübingen, Institute of Pathology and
Neuropathology, Tübingen, Germany
| | - M Börries
- University Medical Center Freiburg, Institute of Medical Bioinformatics
und Systems Medicine IBSM, Freiburg, Germany
| | - CM Niemeyer
- University Medical Center Freiburg, Center for Pediatrics, Department
of Pediatric Hematology and Oncology, Freiburg, Germany
| | - I Teichert-von Lüttichau
- Kinderklinik Muenchen Schwabing, Department of Pediatrics and
Children's Cancer Research Center, TUM School of Medicine, Technical
University of Munich, Munich, Germany
| | - M Erlacher
- University Medical Center Freiburg, Center for Pediatrics, Department
of Pediatric Hematology and Oncology, Freiburg, Germany
| |
Collapse
|
2
|
Hagenbourger F, Fernandez-Orth J, Bohler S, Weiss JM, Andrieux G, Börries M, Niemeyer CM, Erlacher M. Characterization of cooperating mechanisms in GATA2
syndrome. KLINISCHE PADIATRIE 2022. [DOI: 10.1055/s-0042-1748717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- F Hagenbourger
- University Medical Center Freiburg, Center for Pediatrics and
Adolescent Medicine, Department of Pediatric Hematology and Oncology, Freiburg,
Germany
- MOTI-VATE Graduate School, Faculty of Medicine, University of Freiburg,
Freiburg, Germany
| | - J Fernandez-Orth
- University Medical Center Freiburg, Center for Pediatrics and
Adolescent Medicine, Department of Pediatric Hematology and Oncology, Freiburg,
Germany
| | - S Bohler
- University Medical Center Freiburg, Center for Pediatrics and
Adolescent Medicine, Department of Pediatric Hematology and Oncology, Freiburg,
Germany
| | - JM Weiss
- University Medical Center Freiburg, Center for Pediatrics and
Adolescent Medicine, Department of Pediatric Hematology and Oncology, Freiburg,
Germany
| | - G Andrieux
- University Medical Center Freiburg, Institute of Medical Bioinformatics
und Systems Medicine IBSM, Freiburg, Germany
| | - M Börries
- University Medical Center Freiburg, Institute of Medical Bioinformatics
und Systems Medicine IBSM, Freiburg, Germany
| | - CM Niemeyer
- University Medical Center Freiburg, Center for Pediatrics and
Adolescent Medicine, Department of Pediatric Hematology and Oncology, Freiburg,
Germany
| | - M Erlacher
- University Medical Center Freiburg, Center for Pediatrics and
Adolescent Medicine, Department of Pediatric Hematology and Oncology, Freiburg,
Germany
| |
Collapse
|
3
|
Saettini F, Coliva T, Vendemini F, Moratto D, Savoldi G, Borlenghi E, Masetti R, Niemeyer CM, Biondi A, Balduzzi A, Bonanomi S. When to suspect GATA2 deficiency in pediatric patients: from complete blood count to diagnosis. Pediatr Hematol Oncol 2021; 38:510-514. [PMID: 33726626 DOI: 10.1080/08880018.2020.1863536] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- F Saettini
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
| | - T Coliva
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
| | - F Vendemini
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
| | - D Moratto
- Flow cytometry Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy
| | - G Savoldi
- Genetics Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy
| | - E Borlenghi
- Department of Hematology, Spedali Civili, Brescia, Italy
| | - R Masetti
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Bologna, Bologna, Italy
| | - C M Niemeyer
- Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany
| | - A Biondi
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
| | - A Balduzzi
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
| | - S Bonanomi
- Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy
| |
Collapse
|
4
|
Frankiewicz A, Peczynski C, Giebel S, Harrington A, Socié G, Niederwieser D, Scheid C, Bornhäuser M, Kröger N, Elmaagacli A, Afanasyev B, Dreger P, Rössig C, Blaise D, Kratz C, Yakoub-Agha I, Kremens B, Niemeyer CM, Wulf G, Blau I, Penack O, Greinix H, Basak GW. Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT. Front Immunol 2020; 11:1537. [PMID: 32793210 PMCID: PMC7390847 DOI: 10.3389/fimmu.2020.01537] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Accepted: 06/11/2020] [Indexed: 11/13/2022] Open
Abstract
Acute graft-vs.-host disease (aGvHD) is one of the most frequent causes of transplant-related mortality (TRM) after allogeneic hematopoietic cell transplantation (alloHCT). Its treatment is complex and costly. The aim of this study was to retrospectively analyze the impact of country-specific socioeconomic factors on outcome of patients who experience severe aGvHD. Adults with hematological malignancies receiving alloHCT from either HLA-matched siblings (n = 1,328) or unrelated donors (n = 2,824) developing grade 3 or 4 aGvHD were included. In univariate analysis, the probability of TRM at 2 years was increased for countries with lower current Health Care Expenditure (HCE, p = 0.04), lower HCE as % of Gross Domestic Product per capita (p = 0.003) and lower values of the Human Development Index (p = 0.02). In a multivariate model, the risk of TRM was most strongly predicted by current HCE (HR = 0.76, p = 0.006). HCE >median was also associated with reduced risk of the overall mortality (HR 0.73, p = 0.0006) and reduced risk of treatment failure (either relapse or TRM; HR 0.77, p = 0.004). We conclude that country-specific socioeconomic factors, in particular current HCE, are strongly associated with survival of patients who experience severe aGvHD.
Collapse
Affiliation(s)
- Andrzej Frankiewicz
- The Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland
| | | | - Sebastian Giebel
- The Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland
| | - Alenca Harrington
- EBMT Paris Study Office/CEREST-TC Hôpital Saint Antoine, Paris, France
| | - Gerard Socié
- Hopital St. Louis, Department of Hematology - BMT 1, Paris, France
| | - Dietger Niederwieser
- Division of Hematology, Oncology and Hemostasiology, University Hospital Leipzig, Leipzig, Germany
| | - Christoph Scheid
- I. Department of Medicine, University of Cologne, Cologne, Germany
| | - Martin Bornhäuser
- Universitaetsklinikum Dresden Medizinische Klinik und Poliklinik, Dresden, Germany
| | - Nicolaus Kröger
- Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany
| | - Ahmet Elmaagacli
- Department of Haematology, Asklepios Klinik St. Georg, Hamburg, Germany
| | - Boris Afanasyev
- Raisa Gorbacheva Memorial Research Institute for Paediatric Oncology, Hematology, and Transplantation, First State Pavlov Medical University of St. Petersburg, St. Petersburg, Russia
| | - Peter Dreger
- University of Heidelberg Medizinische Klinik und Poliklinik, Heidelberg, Germany
| | - Claudia Rössig
- Universitaetsklinikum Muenster Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie, Münster, Germany
| | - Didier Blaise
- Programme de Transplantation & Therapie Cellulaire Centre de Recherche en Cancérologie de Marseille Institut Paoli Calmettes, Marseille, France
| | - Christian Kratz
- Department of Pediatric Haematology/Oncology, Hannover Medical University, Hanover, Germany
| | | | - Bernhard Kremens
- Department of Pediatric Hematology/Oncology, University Hospital, Essen, Germany
| | - Charlotte Marie Niemeyer
- Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Centre, Freiburg, Germany
| | - Gerald Wulf
- Universitaetsklinikum Goettingen Abteilung Hämatologie und Onkologie, Gottingen, Germany
| | - Igor Blau
- Department of Hematology, Oncology and Tumorimmunology, Charite Universitätsmedizin Berlin, Berlin, Germany
| | - Olaf Penack
- Department of Hematology, Oncology and Tumorimmunology, Charite Universitätsmedizin Berlin, Berlin, Germany
| | - Hildegard Greinix
- Klinische Abteilung für Hämatologie, Universitätsklinik für Innere Medizin, Graz, Austria
| | - Grzegorz W Basak
- Department of Haematology, Oncology and Internal Medicine, Medical Uniwersity of Warsaw, Warsaw, Poland
| |
Collapse
|
5
|
Pastor V, Hirabayashi S, Karow A, Wehrle J, Kozyra EJ, Nienhold R, Ruzaike G, Lebrecht D, Yoshimi A, Niewisch M, Ripperger T, Göhring G, Baumann I, Schwarz S, Strahm B, Flotho C, Skoda RC, Niemeyer CM, Wlodarski MW. Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants. Leukemia 2016; 31:759-762. [DOI: 10.1038/leu.2016.342] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
6
|
Krombholz CF, Fluhr S, Niemeyer CM, Flotho C, Erlacher M. Antileukemic activity of the azacitidine in a xenograft model of juvenile myelomonocytic leukemia. Klin Padiatr 2016. [DOI: 10.1055/s-0036-1582499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
7
|
Byrgazov K, Kastner R, Gorna M, Hoermann G, Koenig M, Lucini CB, Ulreich R, Benesch M, Strenger V, Lackner H, Schwinger W, Sovinz P, Haas OA, van den Heuvel-Eibrink M, Niemeyer CM, Hantschel O, Valent P, Superti-Furga G, Urban C, Dworzak MN, Lion T. NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors. Leukemia 2015; 31:237-240. [PMID: 27573554 PMCID: PMC5220134 DOI: 10.1038/leu.2016.250] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- K Byrgazov
- Children's Cancer Research Institute, Vienna, Austria
| | - R Kastner
- Children's Cancer Research Institute, Vienna, Austria
| | - M Gorna
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Science, Vienna, Austria
| | - G Hoermann
- Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
| | - M Koenig
- Children's Cancer Research Institute, Vienna, Austria
| | - C B Lucini
- Children's Cancer Research Institute, Vienna, Austria
| | - R Ulreich
- Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
| | - M Benesch
- Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
| | - V Strenger
- Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
| | - H Lackner
- Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
| | - W Schwinger
- Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
| | - P Sovinz
- Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
| | - O A Haas
- Children's Cancer Research Institute, Vienna, Austria
| | - M van den Heuvel-Eibrink
- Department of Pediatric Hemato-Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.,Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - C M Niemeyer
- Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany
| | - O Hantschel
- Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - P Valent
- Division of Hematology and Hemostaseology, Department of Internal Medicine, Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria
| | - G Superti-Furga
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Science, Vienna, Austria
| | - C Urban
- Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
| | - M N Dworzak
- Children's Cancer Research Institute, Vienna, Austria.,St Anna Children's Hospital, Vienna, Austria
| | - T Lion
- Children's Cancer Research Institute, Vienna, Austria.,Department of Pediatrics, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
8
|
Krombholz CF, Meier A, Fluhr S, Niemeyer CM, Erlacher M, Flotho C. Stability of DNA methylation signatures in a long-term murine xenograft system of juvenile myelomonocytic leukemia. Klin Padiatr 2015. [DOI: 10.1055/s-0035-1550252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
9
|
Erlacher M, Grünert SC, Cseh A, Steinfeld R, Salzer U, Lausch E, Nosswitz U, Dückers G, Niehues T, Ehl S, Niemeyer CM, Speckmann C. Reversible pancytopenia and immunodeficiency in a patient with hereditary folate malabsorption. Pediatr Blood Cancer 2015; 62:1091-4. [PMID: 25504888 DOI: 10.1002/pbc.25364] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Accepted: 10/27/2014] [Indexed: 01/19/2023]
Abstract
Mutations in SLC46A1 result in a defect of the proton coupled folate transporter (PCFT) and are the basis of hereditary folate malabsorption (HFM). Patients with HFM frequently present with neurodevelopmental delay and megaloblastic anemia. Some cases may be complicated by additional lymphopenia and immunodeficiency. We report a patient with a new homozygous mutation in the SLC46A1 gene. The boy presented with early-onset pancytopenia and secondary immunodeficiency. We provide clinical and molecular observations that extend the phenotypic description of HFM and highlight diagnostic as well as therapeutic pitfalls in this rare condition.
Collapse
Affiliation(s)
- Miriam Erlacher
- Department of Pediatrics and Adolescent Medicine, University Medical Center, Freiburg, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Niemeyer CM, Baumgarten E, Holldack J, Meier I, Trenn G, Jobke A, Eckhardt KU, Reiter A, Sauter S, Riehm H. Treatment trial with recombinant human erythropoietin in children with congenital hypoplastic anemia. Contrib Nephrol 2015; 88:276-80; discussion 281. [PMID: 2040190 DOI: 10.1159/000419537] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
11
|
Harttrampf AC, Schupp W, Timme S, Niemeyer CM, Otten JE, Rössler J. Surgical management of extranasal nasal glioma. J Eur Acad Dermatol Venereol 2015; 30:1209-11. [PMID: 25820156 DOI: 10.1111/jdv.13129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- A C Harttrampf
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center, Freiburg, Germany
| | - W Schupp
- Department of Oral and Maxillofacial Surgery, University Medical Center, Freiburg, Germany
| | - S Timme
- Department of Pathology, University Medical Center, Freiburg, Germany
| | - C M Niemeyer
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center, Freiburg, Germany
| | - J E Otten
- Department of Oral and Maxillofacial Surgery, University Medical Center, Freiburg, Germany
| | - J Rössler
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center, Freiburg, Germany
| |
Collapse
|
12
|
Krombholz CF, Aumann K, Bertele D, Meier A, Niemeyer CM, Flotho C, Erlacher M. Rag2null/γcnull mice are suitable for long-term in vivo propagation of juvenile myelomonocytic leukemia. Klin Padiatr 2014. [DOI: 10.1055/s-0034-1374827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Fluhr S, Meier A, Krombholz CF, Niemeyer CM, Flotho C. Epigenetic changes accompany altered hemoglobin regulation in juvenile myelomonocytic leukemia. Klin Padiatr 2014. [DOI: 10.1055/s-0034-1374825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
14
|
Krombholz CF, Erlacher M, Bertele D, Niemeyer CM, Flotho C. Xenologous engraftment of juvenile myelomonocytic leukemia in BalbC/Rag2null/γcnull mice. Klin Padiatr 2013. [DOI: 10.1055/s-0033-1343638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
15
|
Fluhr S, Witte T, Krombholz CF, Plass C, Niemeyer CM, Flotho C. Prognostic relevance of disordered epigenetic regulation in juvenile myelomonocytic leukemia. Klin Padiatr 2013. [DOI: 10.1055/s-0033-1343633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
16
|
Flotho C, Vraetz T, Lang P, Niemeyer CM, Strahm B. Successful double umbilical cord blood transplantation for relapsed juvenile myelomonocytic leukemia. Leukemia 2012; 27:988-9. [PMID: 23000834 DOI: 10.1038/leu.2012.273] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
17
|
Bertele D, Labi V, Woess C, Grothe G, Schwemmers S, Pahl HL, Geley S, Kunze M, Niemeyer CM, Villunger A, Erlacher M. Haematopoietic Stem Cell Survival and Transplantation Efficacy is Limited by the BH3-only Proteins Bim and Bmf. Klin Padiatr 2012. [DOI: 10.1055/s-0032-1310488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
18
|
Rössler J, Schill T, Bähr A, Truckenmüller W, Noellke P, Niemeyer CM. Propranolol for proliferating infantile haemangioma is superior to corticosteroid therapy--a retrospective, single centre study. J Eur Acad Dermatol Venereol 2011; 26:1173-5. [PMID: 22035186 DOI: 10.1111/j.1468-3083.2011.04314.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
19
|
Strahm B, Nöllke P, Zecca M, Korthof ET, Bierings M, Furlan I, Sedlacek P, Chybicka A, Schmugge M, Bordon V, Peters C, O'Marcaigh A, de Heredia CD, Bergstraesser E, Moerloose BD, van den Heuvel-Eibrink MM, Starý J, Trebo M, Wojcik D, Niemeyer CM, Locatelli F. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia 2011; 25:455-62. [PMID: 21212791 DOI: 10.1038/leu.2010.297] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We report on the outcome of children with advanced primary myelodysplastic syndrome (MDS) transplanted from an HLA-matched sibling (MSD) or an unrelated donor (UD) following a preparative regimen with busulfan, cyclophosphamide and melphalan. Ninety-seven patients with refractory anemia with excess blasts (RAEB, n=53), RAEB in transformation (RAEB-T, n=29) and myelodysplasia-related acute myeloid leukemia (MDR-AML, n=15) enrolled in the European Working Group of MDS in Childhood (EWOG-MDS) 98 study and given hematopoietic stem cell transplantation (HSCT) were analyzed. Median age at HSCT was 11.1 years (range 1.4-19.0). Thirty-nine children were transplanted from an MSD, whereas 58 were given the allograft from a UD (n=57) or alternative family donor (n=1). Stem cell source was bone marrow (n=69) or peripheral blood (n=28). With a median follow-up of 3.9 years (range 0.1-10.9), the 5-year probability of overall survival is 63%, while the 5-year cumulative incidence of transplantation-related mortality (TRM) and relapse is 21% each. Age at HSCT greater than 12 years, interval between diagnosis and HSCT longer than 4 months, and occurrence of acute or extensive chronic graft-versus-host disease were associated with increased TRM. The risk of relapse increased with more advanced disease. This study indicates that HSCT following a myeloablative preparative regimen offers a high probability of survival for children with advanced MDS.
Collapse
Affiliation(s)
- B Strahm
- Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University of Freiburg, Freiburg, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
A novel HLA-C allele, HLA-Cw*06:20 differs from HLA-Cw*06:02 by one nucleotide exchange.
Collapse
Affiliation(s)
- F Emmerich
- Transfusion Medicine, University Medical Center Freiburg, Freiburg, Germany.
| | | | | |
Collapse
|
21
|
Ripperger T, Steinemann D, Göhring G, Finke J, Niemeyer CM, Strahm B, Schlegelberger B. A novel pedigree with heterozygous germline RUNX1 mutation causing familial MDS-related AML: can these families serve as a multistep model for leukemic transformation? Leukemia 2009; 23:1364-6. [PMID: 19387465 DOI: 10.1038/leu.2009.87] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
22
|
Rössler J, Odenthal E, Geoerger B, Gerstenmeyer A, Lagodny J, Niemeyer CM, Vassal G. EGFR inhibition using gefitinib is not active in neuroblastoma cell lines. Anticancer Res 2009; 29:1327-1333. [PMID: 19414383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
BACKGROUND Inhibition of the epidermal growth factor receptor (EGFR), using a tyrosine kinase inhibitor such as gefitinib, was suggested to be a new treatment approach for neuroblastoma. MATERIAL AND METHODS EGFR expression and gene mutation were studied by reversetranscriptase-polxmerase chain reacting, fluorescence-activated cell sorting and gene sequencing in six neuroblastoma cell lines. In vitro cytotoxicity of gefitinib 0.1-10 microM alone or in combination with topotecan, vincristine and 9-cis retinoic acid (9cisRA) was determined by MTT proliferation assay. RESULTS EGFR overexpression and gene mutations were absent in all cell lines tested. Inhibition of cell viability of 62-85% was found at 10 microM gefitinib, concentrations that, however, can clinically not be reached. In addition, gefitinib increased inhibitory effects of topotecan, vincristine and RA by 10-15% . CONCLUSION Our in vitro data do not support the use of gefitinib as monotherapy in neuroblastoma and its chemosensitizing effects appear minor.
Collapse
Affiliation(s)
- Jochen Rössler
- Department of Pediatrics and Adolescent Medicine, University Hospital of Freiburg, 79106 Freiburg, Germany.
| | | | | | | | | | | | | |
Collapse
|
23
|
Kratz CP, Holter S, Etzler J, Lauten M, Pollett A, Niemeyer CM, Gallinger S, Wimmer K. Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome. J Med Genet 2009; 46:418-20. [PMID: 19293170 DOI: 10.1136/jmg.2008.064212] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Biallelic germline mutations in the mismatch repair genes MLH1, MSH2, MSH6 or PMS2 cause a recessive childhood cancer syndrome characterised by early-onset malignancies and signs reminiscent of neurofibromatosis type 1 (NF1). Alluding to the underlying genetic defect, we refer to this syndrome as constitutional mismatch repair-deficiency (CMMR-D) syndrome. The tumour spectrum of CMMR-D syndrome includes haematological neoplasias, brain tumours and Lynch syndrome-associated tumours. Other tumours, such as neuroblastoma, Wilm tumour, ovarian neuroectodermal tumour or infantile myofibromatosis, have so far been found only in individual cases. RESULTS We analysed two consanguineous families that had members with suspected CMMR-D syndrome who developed rhabdomyosarcoma among other neoplasias. In the first family, we identified a pathogenic PMS2 mutation for which the affected patient was homozygous. In family 2, immunohistochemistry analysis showed isolated loss of PMS2 expression in all tumours in the affected patients, including rhabdomyosarcoma itself and the surrounding normal tissue. Together with the family history and microsatellite instability observed in one tumour this strongly suggests an underlying PMS2 alteration in family 2 also. CONCLUSION Together, these two new cases show that rhabdomyosarcoma and possibly other embryonic tumours, such as neuroblastoma and Wilm tumour, belong to the tumour spectrum of CMMR-D syndrome. Given the clinical overlap of CMMR-D syndrome with NF1, we suggest careful examination of the family history in patients with embryonic tumours and signs of NF1 as well as analysis of the tumours for loss of one of the mismatch repair genes and microsatellite instability. Subsequent mutation analysis will lead to a definitive diagnosis of the underlying disorder.
Collapse
Affiliation(s)
- C P Kratz
- Division of Clinical Genetics, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University Innsbruck, Schoepfstr. 41, 6020 Innsbruck, Austria
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Erlacher M, Labi V, Bertele D, Fischer N, Niemeyer CM, Villunger A. Displacement of wild type lymphopoiesis by bone marrow cells lacking the BH3-only proteins BIM or BMF but not puma. Klin Padiatr 2009. [DOI: 10.1055/s-0029-1222633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
25
|
Rössler J, Wehl G, Niemeyer CM. Evaluating systemic prednisone therapy for proliferating haemangioma in infancy. Eur J Pediatr 2008; 167:813-5. [PMID: 17676341 DOI: 10.1007/s00431-007-0561-5] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2007] [Revised: 06/12/2007] [Accepted: 06/26/2007] [Indexed: 10/23/2022]
Abstract
In this study, we reviewed the history of 38 children with proliferating haemangiomas treated with systemic corticosteroids at our institution between 2000 and 2002. Prednisone was administered at an initial dose of 2 mg/kg per day for 2 weeks followed by a dose of 1 mg/kg per day for another 2-4 weeks and consecutive slow tapering over an additional 4-5 months. For 93% of the children, this protocol was successful in reducing the size of the haemangioma by more than 25% after 2 weeks of treatment. Side effects were moderate and reversible after cessation of therapy.
Collapse
Affiliation(s)
- Jochen Rössler
- Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University of Freiburg, Freiburg, Germany.
| | | | | |
Collapse
|
26
|
Niemeyer CM, Kratz CP. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol 2008; 140:610-24. [DOI: 10.1111/j.1365-2141.2007.06958.x] [Citation(s) in RCA: 123] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
27
|
Reimann C, Kloeckener-Gruissem B, Niemeyer CM, Vanscheidt W. Late manifestation of dyskeratosis congenita presenting as chronic dermal ulcer in a 37-year-old man. J Eur Acad Dermatol Venereol 2007; 22:897-8. [PMID: 18070020 DOI: 10.1111/j.1468-3083.2007.02530.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
Kratz CP, Niemeyer CM, Jüttner E, Kartal M, Weninger A, Schmitt-Graeff A, Kontny U, Lauten M, Utzolino S, Rädecke J, Fonatsch C, Wimmer K. Childhood T-cell non-Hodgkin's lymphoma, colorectal carcinoma and brain tumor in association with café-au-lait spots caused by a novel homozygous PMS2 mutation. Leukemia 2007; 22:1078-80. [PMID: 18007577 DOI: 10.1038/sj.leu.2405008] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
29
|
Meissner PE, Jappe U, Niemeyer CM, Peters AM, Kulozik A, Zilow EP. Pyoderma Gangraenosum, a Rare, but Potentially Fatal Complication in Paediatric Oncology Patients. Klin Padiatr 2007; 219:296-9. [PMID: 16865656 DOI: 10.1055/s-2006-933544] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Pyoderma gangraenosum (PG) is a serious chronic, ulcerative skin disorder afflicting both adults and children. As PG is often associated with systemic diseases (>50%) such as inflammatory bowel disease, rheumatoid arthritis or haematological disorders, it requires a multidisciplinary approach. This disorder is not commonly reported in paediatrics; therefore children with PG represent a particularly difficult diagnostic challenge. Clinical diagnosis is often delayed and PG is only considered after eliminating other causes of cutaneous ulcers. We report a 4-year-old boy with secondary myelodysplastic syndrome following treatment for acute lymphoblastic leukaemia who presented with a massive inflammatory, ulcerative proliferation of the lower lip which was diagnosed as PG. We have reviewed the literature with reference to diagnostic criteria and treatment options of this disorder that is particularly rare in childhood.
Collapse
Affiliation(s)
- P E Meissner
- Department of Neonatology, Heidelberg University, Germany.
| | | | | | | | | | | |
Collapse
|
30
|
Kratz CP, Niemeyer CM, Karow A, Volz-Fleckenstein M, Schmitt-Gräff A, Strahm B. Congenital transfusion-dependent anemia and thrombocytopenia with myelodysplasia due to a recurrent GATA1(G208R) germline mutation. Leukemia 2007; 22:432-4. [PMID: 17713552 DOI: 10.1038/sj.leu.2404904] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
31
|
Strahm B, Locatelli F, Bader P, Ehlert K, Kremens B, Zintl F, Führer M, Stachel D, Sykora KW, Sedlacek P, Baumann I, Niemeyer CM. Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplant 2007; 40:329-33. [PMID: 17589538 DOI: 10.1038/sj.bmt.1705730] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Myelodysplastic syndromes (MDS) are a heterogenous group of acquired hematopoietic stem cell disorders. Refractory cytopenia (RC) is the most common subtype of childhood MDS and hematopoietic stem cell transplantation (HSCT) is the only curative treatment. HSCT following a myeloablative preparative regimen is associated with a low probability of relapse and considerable transplant-related mortality. In the present European Working Groups of MDS pilot study, we investigated whether a reduced intensity conditioning regimen (RIC) is able to offer reduced toxicity without increased rates of graft failure or relapse. Nineteen children with RC were transplanted from an unrelated donor following RIC consisting of fludarabine, thiotepa and anti-thymocyte globulin. Three patients experienced graft failure. Neutrophil and platelet engraftment occurred at a median time of 23 and 30 days, respectively. Cumulative incidence of grade II-IV and grade III and IV acute graft-versus-host disease (GVHD) was 0.48 and 0.13, respectively; three patients developed extensive chronic GVHD. Although infections were the predominant complications, only one patient with extensive chronic GVHD died from infectious complications. Overall and event-free survival at 3 years were 0.84 and 0.74, respectively. In conclusion, our results were comparable to those of patients treated with myeloablative HSCT. Long-term follow-up is needed to demonstrate the expected reduction in long-term sequelae.
Collapse
Affiliation(s)
- B Strahm
- Pediatric Hematology and Oncology, Center for Pediatric and Adolescent Medicine, University of Freiburg, Mathildenstrasse 1, 79102 Freiburg, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Hanke CA, Roessler J, Stegmaier S, Koscielniak E, Niemeyer CM, Kontny U. Alveolar rhabdomyosarcoma mimicking lymphoma with bone marrow involvement. Eur J Pediatr 2007; 166:505-6. [PMID: 17008999 DOI: 10.1007/s00431-006-0269-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2006] [Accepted: 07/19/2006] [Indexed: 10/24/2022]
Affiliation(s)
- Christof Andreas Hanke
- Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University of Freiburg, Mathildenstrasse 1, 79106, Freiburg, Germany
| | | | | | | | | | | |
Collapse
|
33
|
Karow A, Steinemann D, Göhring G, Hasle H, Greiner J, Harila-Saari A, Flotho C, Zenker M, Schlegelberger B, Niemeyer CM, Kratz CP. Clonal duplication of a germline PTPN11 mutation due to acquired uniparental disomy in acute lymphoblastic leukemia blasts from a patient with Noonan syndrome. Leukemia 2007; 21:1303-5. [PMID: 17361219 DOI: 10.1038/sj.leu.2404651] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
34
|
Flotho C, Steinemann D, Mullighan CG, Neale G, Mayer K, Kratz CP, Schlegelberger B, Downing JR, Niemeyer CM. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11. Oncogene 2007; 26:5816-21. [PMID: 17353900 DOI: 10.1038/sj.onc.1210361] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Juvenile myelomonocytic leukemia (JMML) is a malignant hematopoietic disorder whose proliferative component is a result of RAS pathway deregulation caused by somatic mutation in the RAS or PTPN11 oncogenes or in patients with underlying neurofibromatosis type 1 (NF-1), by loss of NF1 gene function. To search for potential collaborating genetic abnormalities, we used oligonucleotide arrays to analyse over 116 000 single-nucleotide polymorphisms across the genome in 16 JMML samples with normal karyotype. Evaluation of the SNP genotypes identified large regions of homozygosity on chromosome 17q, including the NF1 locus, in four of the five samples from patients with JMML and NF-1. The homozygous region was at least 55 million base pairs in each case. The genomic copy number was normal within the homozygous region, indicating uniparental disomy (UPD). In contrast, the array data provided no evidence for 17q UPD in any of the 11 JMML cases without NF-1. We used array-based comparative genomic hybridization to confirm 17q disomy, and microsatellite analysis was performed to verify homozygosity. Mutational analysis demonstrated that the inactivating NF1 lesion was present on both alleles in each case. In summary, our data indicate that a mitotic recombination event in a JMML-initiating cell led to 17q UPD with homozygous loss of normal NF1, provide confirmatory evidence that the NF1 gene is crucial for the increased incidence of JMML in NF-1 patients, and corroborate the concept that RAS pathway deregulation is central to JMML pathogenesis.
Collapse
MESH Headings
- Child, Preschool
- Chromosome Mapping
- Chromosomes, Human/genetics
- DNA, Neoplasm
- Female
- Genes, ras/genetics
- Genome, Human
- Humans
- Infant
- Intracellular Signaling Peptides and Proteins/genetics
- Leukemia, Myelomonocytic, Chronic/genetics
- Leukemia, Myelomonocytic, Chronic/physiopathology
- Male
- Mutation
- Neurofibromatosis 1/genetics
- Neurofibromatosis 1/physiopathology
- Neurofibromin 1/genetics
- Polymorphism, Single Nucleotide/genetics
- Protein Tyrosine Phosphatase, Non-Receptor Type 1
- Protein Tyrosine Phosphatase, Non-Receptor Type 11
- Protein Tyrosine Phosphatases/genetics
- Uniparental Disomy/genetics
Collapse
Affiliation(s)
- C Flotho
- Division of Pediatric Hematology-Oncology, University of Freiburg, Freiburg, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
Polymyositis is a rare manifestation of cGvHD in adult patients following allogeneic BMT. Here, we report on a 2.1-yr-old girl who presented with a facial swelling and rapidly developing respiratory failure eight months after BMT for severe combined immunodeficiency. Possible infectious agents and autoimmune origin other than cGvHD were excluded. The girl responded promptly to steroid therapy and remains well without other signs of cGvHD four months later.
Collapse
Affiliation(s)
- R Klein
- Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany.
| | | | | | | | | | | |
Collapse
|
36
|
Kratz CP, Niemeyer CM, Thomas C, Bauhuber S, Matejas V, Bergsträsser E, Flotho C, Flores NJ, Haas O, Hasle H, van den Heuvel-Eibrink MM, Kucherlapati RS, Lang P, Roberts AE, Starý J, Strahm B, Swanson KD, Trebo M, Zecca M, Neel B, Locatelli F, Loh ML, Zenker M. Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia. Leukemia 2007; 21:1108-9. [PMID: 17315019 DOI: 10.1038/sj.leu.2404620] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
37
|
Metzner A, Horstmann MA, Fehse B, Ortmeyer G, Niemeyer CM, Stocking C, Mayr GW, Jücker M. Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations. Gene Ther 2007; 14:699-703. [PMID: 17268534 DOI: 10.1038/sj.gt.3302912] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Juvenile myelomonocytic leukemia (JMML) is a malignant disease of early childhood characterized by a hypersensitivity to granulocyte/macrophage colony-stimulating factor (GM-CSF). Mutations in RAS or PTPN11 are frequently detected in JMML patients. The SH2-containing inositol 5-phosphatase 1 (SHIP-1) is a negative regulator of GM-CSF signaling, and inactivation of SHIP-1 in mice results in a myeloproliferative disease. Here, we report the effects of SHIP-1 expression on GM-CSF-dependent proliferation and colony formation of human hematopoietic cells. After retroviral-mediated transduction of SHIP-1 into CD34+ cells from cord blood of healthy newborns or peripheral blood of JMML patients carrying mutations in KRAS2 or PTPN11, we observed a reduction in GM-CSF-dependent proliferation and colony formation. An enzymatically inactive form of SHIP-1 (D672A) had no effect. These data indicate that SHIP-1 can effectively block GM-CSF hypersensitivity in JMML progenitor cells with mutations in KRAS2 or PTPN11 and may be a useful approach for the treatment of JMML patients.
Collapse
Affiliation(s)
- A Metzner
- University Medical Center Hamburg-Eppendorf, Center of Experimental Medicine, Institute of Biochemistry and Molecular Biology I, Cellular Signal Transduction, Hamburg, Germany
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Yoshimi A, Mohamed M, Bierings M, Urban C, Korthof E, Zecca M, Sykora KW, Duffner U, Trebo M, Matthes-Martin S, Sedlacek P, Klingebiel T, Lang P, Führer M, Claviez A, Wössmann W, Pession A, Arvidson J, O'Marcaigh AS, van den Heuvel-Eibrink MM, Starý J, Hasle H, Nöllke P, Locatelli F, Niemeyer CM. Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia 2007; 21:556-60. [PMID: 17268527 DOI: 10.1038/sj.leu.2404537] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
39
|
Zecca M, Bergamaschi G, Kratz C, Bergsträsser E, Danesino C, De Filippi P, Hasle H, Lisini D, Locatelli F, Pession A, Sainati L, Starý J, Trebo M, van den Heuvel-Eibrink M, Wójcik D, Niemeyer CM. JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia. Leukemia 2006; 21:367-9. [PMID: 17151700 DOI: 10.1038/sj.leu.2404484] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
40
|
Lagodny J, Jüttner E, Kayser G, Niemeyer CM, Rössler J. Lymphangiogenesis and its regulation in human neuroblastoma. Biochem Biophys Res Commun 2006; 352:571-7. [PMID: 17140547 DOI: 10.1016/j.bbrc.2006.11.062] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2006] [Accepted: 11/13/2006] [Indexed: 11/16/2022]
Abstract
For the first time, we could detect lymph vessels in neuroblastoma (NB) by immunohistochemistry with the antibody D2_40. Furthermore, we demonstrate expression of the lymphangiogenic factors VEGF-C and VEGF-D and their receptors VEGFR-2 and VEGFR-3 in NB in vitro and in vivo by RT-PCR. However, addition of recombinant human VEGF-C or -D results in the absence of autocrine growth stimulus in NB cells. Treatment of NB cells with retinoic acid did not lead to a change in VEGF-C or VEGF-D mRNA expression. Incubation of the NB cells Lan-5 with 5-Aza-2'-deoxycytidine led to the up-regulation of VEGF-C mRNA expression, suggesting that the promotor of VEGF-C is methylated. Finally, VEGF-C mRNA expression could be effectively down-regulated by transfection with a specific siRNA in the NB cells Kelly. We conclude that lymphangiogenesis is involved in NB biology and that siRNA directed against VEGF-C may have a future role in anti-lymphangiogenic strategies in NB.
Collapse
Affiliation(s)
- Jeanette Lagodny
- Division of Pediatric Hematology/Oncology, Department of Pediatrics and Adolescent Medicine, Mathilsdenstr. 1, 79106 Freiburg, Germany
| | | | | | | | | |
Collapse
|
41
|
Göhring G, Hanke C, Kratz C, Kontny U, Steinemann D, Niemeyer CM, Schlegelberger B. Fluorescence in situ hybridization using the subtelomeric 11q probe as a diagnostic tool for congenital thrombocytopenia. Ann Hematol 2006; 85:883-5. [PMID: 16977432 DOI: 10.1007/s00277-006-0177-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2006] [Accepted: 07/11/2006] [Indexed: 10/24/2022]
|
42
|
Abstract
A new classification of myelodysplastic and myeloproliferative diseases in childhood has greatly facilitated the diagnosis of these uncommon disorders. Because hematopoietic stem cell transplantation (HSCT) can cure more than half of the affected children, palliative treatment strategies often applied in adult myelodysplastic syndrome (MDS) are of little importance in pediatric MDS. Unraveling some of the underlying genetic factors predisposing to MDS at a young age may give important insights into leukemogenesis in the elderly.
Collapse
Affiliation(s)
- Charlotte Marie Niemeyer
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Mathildenstrasse 1, 79106 Freiburg, Germany.
| | | | | |
Collapse
|
43
|
Reimann C, Arola M, Bierings M, Karow A, van den Heuvel-Eibrink MM, Hasle H, Niemeyer CM, Kratz CP. A novel somatic K-Ras mutation in juvenile myelomonocytic leukemia. Leukemia 2006; 20:1637-8. [PMID: 16826224 DOI: 10.1038/sj.leu.2404303] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
44
|
Kratz CP, Nathrath M, Freisinger P, Dressel P, Assmuss HP, Klein C, Yoshimi A, Burdach S, Niemeyer CM. Lethal proliferation of erythroid precursors in a neonate with a germline PTPN11 mutation. Eur J Pediatr 2006; 165:182-5. [PMID: 16369799 DOI: 10.1007/s00431-005-0031-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/02/2005] [Revised: 09/12/2005] [Accepted: 09/18/2005] [Indexed: 11/26/2022]
Abstract
We report a neonate with hypertrophic cardiomyopathy and lethal myeloproliferative disorder with excessively proliferating immature erythroid precursors infiltrating non-hematopoietic organs. Mutational analysis uncovered a germline mutation in the Noonan syndrome/LEOPARD syndrome (NS/LS) gene PTPN11. In conclusion, this case report suggests that congenital myeloproliferative disorders in association with germline PTPN11 mutations may affect the erythroid lineage.
Collapse
Affiliation(s)
- Christian Peter Kratz
- Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Rössler J, Zambrzycka I, Lagodny J, Kontny U, Niemeyer CM. Effect of STI-571 (imatinib mesylate) in combination with retinoic acid and gamma-irradiation on viability of neuroblastoma cells. Biochem Biophys Res Commun 2006; 342:1405-12. [PMID: 16524560 DOI: 10.1016/j.bbrc.2006.02.059] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2006] [Accepted: 02/08/2006] [Indexed: 11/15/2022]
Abstract
Neuroblastoma (NB) expresses the tyrosine kinase receptors c-Kit, PDGFR-alpha and -beta-targets for STI-571. We investigated a possible combination therapy of STI-571 with retinoic acid (RA) and gamma-irradiation on NB cell viability in vitro. Expression of tyrosine kinase receptors and their ligands was examined in 6 NB cell lines by RT-PCR and FACS. The effect on cell viability was determined by MTT assay. Cell viability of all 6 NB cell lines was significantly inhibited after treatment with 20 microM STI-571 for 72h, two cell lines responding already to 10 microM. Cell lines responded irrespective of their mRNA status or cell surface expression of c-Kit, PDGFR-alpha and -beta. Co-incubation with 9-cis RA sensitized cells to the inhibitory effects of STI-571. However, pre-treatment with 9-cis RA resulted in resistance of NB cell lines to STI-571 and gamma-irradiation. Treatment of NB with STI-571 in combination with 9-cis RA might be a therapeutic strategy for patients in consolidation therapy who have completed gamma-irradiation therapy.
Collapse
Affiliation(s)
- Jochen Rössler
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Hospital of Freiburg, Germany.
| | | | | | | | | |
Collapse
|
46
|
Kratz CP, Böll S, Kontny U, Schrappe M, Niemeyer CM, Stanulla M. Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 2005; 20:381-3. [PMID: 16341038 DOI: 10.1038/sj.leu.2404060] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
47
|
Yoshimi A, Bader P, Matthes-Martin S, Starý J, Sedlacek P, Duffner U, Klingebiel T, Dilloo D, Holter W, Zintl F, Kremens B, Sykora KW, Urban C, Hasle H, Korthof E, Révész T, Fischer A, Nöllke P, Locatelli F, Niemeyer CM. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 2005; 19:971-7. [PMID: 15800672 DOI: 10.1038/sj.leu.2403721] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Juvenile myelomonocytic leukemia (JMML) is a clonal myeloproliferative disorder of early childhood. In all, 21 patients with JMML who received donor leukocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT) for either mixed chimerism (MC, n=7) or relapse (n=14) were studied. Six patients had been transplanted from an HLA-matched sibling and 15 from other donors. Six of the 21 patients (MC: 3/7 patients; relapse: 3/14 patients) responded to DLI. Response rate was significantly higher in patients receiving a higher total T-cell dose (> or =1 x 10(7)/kg) and in patients with an abnormal karyotype. None of the six patients receiving DLI from a matched sibling responded. Response was observed in five of six patients who did and in one of 15 children who did not develop acute graft-versus-host disease following DLI (P=0.01). The overall outcome was poor even for the responders. Only one of the responders is alive in remission, two relapsed, and three died of complications. In conclusion, this study shows that some cases of JMML may be sensitive to DLI, this providing evidence for a graft-versus-leukemia effect in JMML. Infusion of a high number of T cells, strategies to reduce toxicity, and cytoreduction prior to DLI may improve the results.
Collapse
Affiliation(s)
- A Yoshimi
- Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University of Freiburg, Freiburg 79106, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Cantù Rajnoldi A, Fenu S, Kerndrup G, van Wering ER, Niemeyer CM, Baumann I. Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). Ann Hematol 2005; 84:429-33. [PMID: 15838669 DOI: 10.1007/s00277-005-1034-4] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2004] [Accepted: 02/22/2005] [Indexed: 10/25/2022]
Abstract
In the absence of genetic abnormalities, the diagnoses of myelodysplastic syndromes (MDS) is primarily based on the presence of dysplasia in blood and marrow cells. Currently, there is no standardized approach to evaluate dysplasia. International cooperative study groups like the European Working Group on MDS in Childhood (EWOG-MDS) depend, however, on a concordance in diagnoses by their national reference centres for morphology. In EWOG-MDS, the morphological diagnoses of all cases enrolled from Scandinavia, the Netherlands, Germany, the Czech Republic, Austria and Italy are established by five experienced pathologists or hematologists cooperating in a morphology board. To study their concordance in evaluating myelodysplastic disorders, members of the morphology board initiated blinded reviews of smears of blood and bone marrow aspirates of known cases. Four features of dysplasia in granulopoiesis, erythropoiesis and megakaryopoiesis were assessed on May-Grünwald-Giemsa stained smears. In a final review of six blinded cases, good concordance for these features was achieved among the five observers. Accurately defined and restrictively applied cellular features of dysplasia are an important tool to improve and ensure the concordance in the diagnosis of MDS among investigators. For cooperative groups, agreement on the evaluation of the morphological assessment of dysplasia is a prerequisite.
Collapse
Affiliation(s)
- A Cantù Rajnoldi
- Dip.to di Medicina di Laboratorio, Istituti Clinici di Perfezionamento, Milan, Italy
| | | | | | | | | | | |
Collapse
|
49
|
Abstract
SUMMARY Stem cell transplantation (SCT) from a histocompatible sibling is treatment of choice for severe aplastic anemia. Survival rates have been reported to be as high as 90% for children. Immunosuppressive therapy (IST) is employed in patients who are not candidates for SCT due to donor unavailability. The addition of cyclosporin A to antilymphocyte globulin has improved the response rate to 70-80%, and survival at 5 years among responders is about 90%. In all, 30% of patients treated by IST suffer from relapse, but long-term prognosis does not appear to be affected by this complication. Juvenile myelomonocytic leukemia (JMML) shares both myelodysplastic and myeloproliferative features. Survival (10-year) of patients with JMML without SCT is only 6%. Children with JMML should be transplanted early in the course of their disease. Conditioning regimen composed of three alkylating agents, busulfan, cyclophosphamide and melphalan has been favored by the EWOG-MDS and EBMT-Pediatric WP in the second half of the 1990s. SCT using this conditioning regimen is capable of curing approximately 50% of patients with JMML. More than 70% of patients with refractory cytopenia and more than 50% of children with advanced MDS are cured of by the early performed allogeneic SCT.
Collapse
Affiliation(s)
- J Starý
- Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic.
| | | | | |
Collapse
|
50
|
Kratz CP, Rogge T, Kopp M, Baumann I, Niemeyer CM. Myelodysplastic features in an infant with cystic fibrosis presenting with anaemia, oedema and failure to thrive. Eur J Pediatr 2005; 164:56-7. [PMID: 15517378 DOI: 10.1007/s00431-004-1548-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2004] [Revised: 08/20/2004] [Accepted: 08/24/2004] [Indexed: 10/26/2022]
Affiliation(s)
- Christian Peter Kratz
- Department of Paediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany.
| | | | | | | | | |
Collapse
|